Hyperkalemic periodic paralysis
| Hyperkalemic periodic paralysis | |
|---|---|
| Synonyms | HyperKPP |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Episodic muscle weakness, muscle stiffness, paralysis |
| Complications | N/A |
| Onset | Childhood or adolescence |
| Duration | Episodic, lasting minutes to hours |
| Types | N/A |
| Causes | Genetic mutation in the SCN4A gene |
| Risks | Potassium-rich foods, exercise, stress |
| Diagnosis | Clinical evaluation, genetic testing |
| Differential diagnosis | Hypokalemic periodic paralysis, paramyotonia congenita |
| Prevention | N/A |
| Treatment | Potassium-lowering medications, dietary management |
| Medication | Thiazide diuretics, carbonic anhydrase inhibitors |
| Prognosis | Variable, generally good with management |
| Frequency | Rare |
| Deaths | N/A |
Hyperkalemic periodic paralysis (HyperPP) is a rare, inherited channelopathy characterized by episodes of muscle weakness or paralysis. HyperPP is a type of periodic paralysis, which includes other disorders such as hypokalemic periodic paralysis and thyrotoxic periodic paralysis.
Symptoms[edit]
The primary symptom of HyperPP is episodic attacks of muscle weakness or paralysis. These episodes often begin in childhood and can vary in severity. The frequency of attacks can range from daily to yearly, and the duration can vary from minutes to days. Other symptoms may include myotonia, a condition in which the muscles are unable to quickly relax after voluntary contraction, and paramyotonia, a condition characterized by prolonged muscle stiffness and difficulty relaxing the muscles.
Causes[edit]
HyperPP is caused by mutations in the SCN4A gene, which provides instructions for making a protein that plays a crucial role in muscles used for movement (skeletal muscles). The SCN4A gene mutations associated with HyperPP result in the production of an abnormal sodium channel protein, which disrupts the flow of sodium ions into muscle cells and leads to the characteristic features of HyperPP.
Diagnosis[edit]
Diagnosis of HyperPP is based on the clinical symptoms, a physical examination, and specialized tests that can help to confirm the diagnosis. These tests may include a serum potassium test, electromyography (EMG), and genetic testing.
Treatment[edit]
Treatment for HyperPP is focused on preventing and managing attacks. This may include avoiding triggers, such as certain foods or medications, and taking medications to help prevent or reduce the severity of attacks. In some cases, treatment may also include physical therapy to help improve muscle strength and function.
See also[edit]
References[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
